BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, December 15, 2025
See today's BioWorld
Home
» CFDA approves GSK's Cervarix as China's first HPV vaccine
To read the full story,
subscribe
or
sign in
.
CFDA approves GSK's Cervarix as China's first HPV vaccine
July 19, 2016
By
Cornelia Zou
HONG KONG – A decade after the U.S. launch, Glaxosmithkline plc's (GSK) Cervarix vaccine to prevent the human papillomavirus (HPV) is in the home stretch to launch as the first HPV vaccine in Mainland China.
BioWorld